Viracta Price Earnings Ratio from 2010 to 2024

VIRX Stock  USD 0.25  0.04  19.05%   
Viracta Therapeutics Price Earnings Ratio yearly trend continues to be fairly stable with very little volatility. Price Earnings Ratio will likely drop to -0.45 in 2024. During the period from 2010 to 2024, Viracta Therapeutics Price Earnings Ratio regression line of annual values had significance of  0 and arithmetic mean of (5.14). View All Fundamentals
 
Price Earnings Ratio  
First Reported
2010-12-31
Previous Quarter
(0.43)
Current Value
(0.45)
Quarterly Volatility
6.93798938
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Viracta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viracta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 324.1 K, Interest Expense of 3.9 M or Selling General Administrative of 13.7 M, as well as many indicators such as Price To Sales Ratio of 5.9, Dividend Yield of 0.0 or PTB Ratio of 1.14. Viracta financial statements analysis is a perfect complement when working with Viracta Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viracta Therapeutics Correlation against competitors.
For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

Latest Viracta Therapeutics' Price Earnings Ratio Growth Pattern

Below is the plot of the Price Earnings Ratio of Viracta Therapeutics over the last few years. It is Viracta Therapeutics' Price Earnings Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viracta Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price Earnings Ratio10 Years Trend
Slightly volatile
   Price Earnings Ratio   
       Timeline  

Viracta Price Earnings Ratio Regression Statistics

Arithmetic Mean(5.14)
Coefficient Of Variation(135.01)
Mean Deviation5.48
Median(1.50)
Standard Deviation6.94
Sample Variance48.14
Range23.1298
R-Value0.69
Mean Square Error27.43
R-Squared0.47
Significance0
Slope1.06
Total Sum of Squares673.90

Viracta Price Earnings Ratio History

2024 -0.45
2023 -0.43
2022 -1.11
2021 -0.57
2020 -0.0337
2019 -1.27
2018 -0.56

About Viracta Therapeutics Financial Statements

Viracta Therapeutics investors use historical fundamental indicators, such as Viracta Therapeutics' Price Earnings Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viracta Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Earnings Ratio(0.43)(0.45)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.